Bismuth Subsalicylate Global Market Report 2025

The bismuth subsalicylate market size has grown strongly in recent years. It will grow from $1.7 billion in 2024 to $1.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historical period can be attributed to factors such as the rising geriatric population, increased disposable income, growing consumer preference for self-medication, a surge in travel-related gastrointestinal issues, and the increased consumption of processed foods contributing to digestive problems.

The bismuth subsalicylate market size is expected to see strong growth in the next few years. It will grow to $2.37 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The projected growth during the forecast period is driven by factors including the increasing prevalence of gastrointestinal disorders, rising demand for over-the-counter (OTC) medications, growing awareness of digestive health, the expansion of the pharmaceutical industry, and the development of healthcare infrastructure in emerging markets. Key trends in the forecast period include the popularity of antacid and anti-nausea medications, the availability of bismuth subsalicylate in both liquid and tablet forms, advancements in drug formulations that improve patient compliance, strategic collaborations between pharmaceutical companies, and the development of bismuth subsalicylate-based branded formulations.

The rising prevalence of gastrointestinal disorders is expected to drive the growth of the bismuth subsalicylate market in the coming years. Gastrointestinal disorders affect the digestive tract, including the stomach, intestines, and related organs, and often result in symptoms such as pain, bloating, and changes in bowel movements. Poor dietary habits, such as excessive consumption of processed foods and insufficient fiber intake, are major contributors to the increase in gastrointestinal disorders, as they disrupt the balance of gut microbiota and impair digestion. Bismuth subsalicylate is commonly used to alleviate gastrointestinal issues such as diarrhea by reducing gut inflammation and inhibiting the growth of harmful bacteria. For instance, a report published by ScienceDirect in May 2025 stated that approximately 23.5 million gastrointestinal endoscopies were performed in 2022, marking a 6% increase from the previous year. Consequently, the growing prevalence of gastrointestinal disorders will drive the demand for bismuth subsalicylate.

The growth of the pharmaceutical industry is expected to fuel the expansion of the bismuth subsalicylate market. The pharmaceutical industry focuses on the research, development, manufacturing, and marketing of medications and therapeutic products to improve health and treat various medical conditions. As chronic diseases become more prevalent globally, the demand for innovative treatments continues to rise, prompting further growth in the pharmaceutical sector. This expansion is enhancing the availability of advanced formulations and distribution channels for bismuth subsalicylate, making it more accessible worldwide as a treatment for gastrointestinal disorders. For example, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) reported in November 2024 that the pharmaceutical industry contributed \$2,295 billion to the global GDP in 2022, with \$755 billion from direct contributions, representing 0.7% of global GDP. The continued growth of the pharmaceutical industry is expected to support the development and distribution of bismuth subsalicylate.

Major companies in the bismuth subsalicylate market are innovating new formulations, such as chewable tablets, to improve medication adherence and provide more effective digestive relief. Chewable tablets are designed to be easier to consume and allow for faster absorption compared to traditional tablets. For example, in May 2025, Wonderbelly, a U.S.-based pharmaceutical company, introduced a dye-free alternative to Pepto-Bismol, offering chewable tablets that provide relief from upset stomach, diarrhea, indigestion, and nausea. These tablets contain the same active ingredient - bismuth subsalicylate - but are formulated without dyes or talc, offering a more consumer-friendly option.

Major players in the bismuth subsalicylate market are Procter & Gamble, GlaxoSmithKline Plc, Perrigo Company Plc, Siegfried AG, Laboratorios Imperiales S.A. de C.V., Shandong Xinhua Pharmaceutical Co. Ltd., Alpha Chemika, JQC (Huayin) Pharmaceutical Co. Ltd., Chr. Olesen Group, Vital Materials Co. Ltd., Shanpar Industries Pvt. Ltd., OCB Pharmaceutical, Muby Chemicals, A. B. Enterprises, Samuh Laxmi, Lumax Pharmaceutical Labs Pvt. Ltd., GB Nitrochem Pvt. Ltd., Indian Platinum Private Limited, Organs Bio Lab Private Limited, Maan Medex Private Limited.

North America was the largest region in the bismuth subsalicylate market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bismuth subsalicylate report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bismuth subsalicylate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bismuth subsalicylate is an over-the-counter medication that alleviates digestive symptoms by coating the stomach lining to protect it from acid, reducing inflammation, and exhibiting mild antibacterial properties. It helps fight bacteria and soothe irritation, while the subsalicylate (a compound related to aspirin) aids in reducing inflammation and intestinal discomfort.

The main forms of bismuth subsalicylate include bismuth subsalicylate tablets, bismuth subsalicylate suspension, and bismuth subsalicylate chewable tablets. Bismuth subsalicylate tablets are solid, swallowable tablets containing a specific amount of the compound. It is distributed through various channels such as online pharmacies, retail pharmacies, supermarkets, hypermarkets, and health and wellness stores. This medication is used for gastrointestinal disorders, diarrhea, nausea, heartburn, and indigestion. It is used by a variety of end-users, including adult consumers, pediatric consumers, healthcare professionals, caretakers, and guardians.

The bismuth subsalicylate market research report is one of a series of new reports that provides bismuth subsalicylate market statistics, including bismuth subsalicylate industry global market size, regional shares, competitors with a bismuth subsalicylate market share, detailed bismuth subsalicylate market segments, market trends and opportunities, and any further data you may need to thrive in the bismuth subsalicylate industry. This bismuth subsalicylate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bismuth subsalicylate market consists of sales of stomach relief caplets, travel sickness relief kits, digestive aid strips, and stomach pain relief lozenges. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.